Pharmacy & Medication Management
Expert articles and analysis related to pharmacy & medication management.
AI Summary â Last 7 Days
CMSâ Medicare drug policy agenda is moving from implementation to codification, with the Trump administrationâs proposed IPAY 2029 Medicare Drug Price Negotiation Program rule drawing detailed pushback from hospitals and policy groups over operational, reimbursement, and access implicationsâissues directly affecting oncology pathways, pharmacy contracting, and VBC total-cost benchmarks. At the same time, litigation and pricing dynamics are creating uncertainty: the D.C. Circuit revived part of Tevaâs IRA challenge as Austedo negotiated-price cuts approach, while Avalere warns that Maximum Fair Price effectuation and statutory inflation rebates could trigger ASP âspiralsâ in competitive drug classes, complicating Part B drug economics for ACOs and specialty care models. For VBC leaders, the near-term priority is scenario planning around negotiated-price implementation, formulary and utilization-management changes in MA/Part D CY 2026â2027 policy, and specialty pharmacy risk embedded in population-based contracts ([AHA comments on CMS proposal](https://news.google.com/rss/articles/CBMiyAFBVV95cUxOYjlZMFFjZDdkMmJtM3p5TUVJNTVBV09OVHQ0NXh6akZrbXNiWTg0bkhLN1k1TUhxVE95eURvemE5YnlIalVVSmxjdkVTaVh1Z3I2UmRYN3JvbGlTYzFhWWE5OENubW
Related Articles
MFP Effectuation and the SDRA: The Possibility of ASP Spirals in Competitive Drug Classes[
Federal appeals court revives part of Teva's IRA case as Austedo price cuts loom
After a lower court rejected Teva's case last fall, a federal appeals court has revived part of the drugmakerâs lawsuit against Medicare negotiations. The DC Circuit Court ruled on Tuesday that Teva...
Response to Senate Finance Committee request for information on policies for lowering drug prices
Response to Senate Finance Committee request for information on policies for lowering drug prices  Brookings
Comments on the Medicare Drug Price Negotiation Program proposed rule for IPAY 2029
Comments on the Medicare Drug Price Negotiation Program proposed rule for IPAY 2029Â Â Brookings
Legislative Proposals Aim to Modify the 340B Program
STAT+: The White House declares âpromises made, promises keptâ on lowering drug prices. Nice try
In its effort to lower drug prices, the White House has declared "promises made, promises kept." That's a narrative that doesn't reflect the full story.
Trump is taking credit for lower list prices. But a Biden-era law did a lot of the heavy lifting
List prices for brand-name drugs have declined significantly in 2026. But the reasons behind it may have more to do with a Biden-era law than any of the Trump administration's recent initiatives, expe...
AHA comments on CMS proposal to codify Medicare Drug Price Negotiation Program regulations
AHA comments on CMS proposal to codify Medicare Drug Price Negotiation Program regulations  American Hospital Association
A recent historic drop in drug prices is largely driven by market forces, Joyce explains
The post A recent historic drop in drug prices is largely driven by market forces, Joyce explains appeared first on USC Schaeffer.
Policy Options to Lower Drug Prices
Policy Options to Lower Drug Prices  Margolis Institute for Health Policy